AEGROS Awarded Collaborative Australian Research Council Linkage Project (ARCLP) Grant to support $1.8M Project
FOR IMMEDIATE RELEASE
Sydney, Australia 25th February 2019 – The Board of Aegros is delighted to advise that the
Australian Research Council (ARC) has awarded the prestigious ARCLP grant to Aegros and their academic collaborators the University of Queensland. The grant was awarded to develop new generation Smart Membranes for industrial applications of Aegros’ patented CyMES plasma fractionation technology. Aegros researchers will work with Professors Steve Mahler, Kris Thurecht and their research groups from the University of Queensland’s Centre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology. The total project budget is estimated around A$1.8M over the next three years.
Dr Kailing Wang, Aegros’ VP for Research and Development said, “This grant will allow the Aegros R&D team to develop a whole range of new product lines.
It is indeed an honour to be awarded this grant and also the opportunity to work with such a high calibre group at The University of Queensland’s Centre for Advanced Imaging and The Australian Institute for Bioengineering and Nanotechnology.
Professor Steven Mahler from The Australian Institute for Bioengineering and Nanotechnology said, “The success rate nationally for such grants is around 32% and therefore the grant is a very competitive one. It is certainly a great opportunity for our Scientists to be collaborating with a commercial partner like Aegros.”
For more information please contact:
Dr Hari Nair
+61 2 9683 8673
Our mission is to develop and become the market leader in the emerging therapeutic plasma markets. The Company will achieve this by integrating the multi patent pending CyMES with existing processes to deliver safer & more affordable therapeutic plasma products.
At Aegros we believe, access to these life saving drugs is a human right and not a privilege. In a nutshell, at Aegros, our mission is to put the Patient 1st through innovation.